Abstract: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are certain salts of 3-O-(3?,3?-dimethylsuccinyl)betulinic acid, also known as “DSB.” The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (“HIV”).
Type:
Application
Filed:
July 17, 2009
Publication date:
September 15, 2011
Applicant:
Myriad Pharmaceuticals, Incorporated
Inventors:
Peter Bullock, Theodore J. Nitz, Gary Sweetapple
Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating brain cancer.
Abstract: The invention relates to drug substance preparations, pharmaceutical compositions and dosage forms containing (R)-(?)-2-(2-fluoro-4-biphenylyl) propionic acid as the active pharmaceutical ingredient, and limited amounts of specific product-related and process-related impurities.
Type:
Application
Filed:
July 31, 2009
Publication date:
April 8, 2010
Applicant:
Myriad Pharmaceuticals, Incorporated
Inventors:
Gaylen M. Zentner, James C. McRea, Mark S. Williams, Stephen J. Martin, Norman T. Smith, Catriona A. Oare
Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
Type:
Application
Filed:
July 10, 2009
Publication date:
March 18, 2010
Applicant:
Myriad Pharmaceuticals, Incorporated
Inventors:
MARK B. ANDERSON, J. Adam Willardsen, Warren S. Weiner, Ashantai Yungai, Robert J. Halter, Yevgeniya Klimova, Kazuyuki Suzuki, Matthew Reeder